| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Muscle, Smooth, Vascular | 69 | 2022 | 1504 | 9.330 |
Why?
|
| Vasoconstriction | 52 | 2022 | 596 | 8.350 |
Why?
|
| Matrix Metalloproteinases | 18 | 2021 | 391 | 7.080 |
Why?
|
| Vasodilation | 38 | 2021 | 944 | 6.920 |
Why?
|
| Matrix Metalloproteinase 2 | 13 | 2022 | 472 | 4.140 |
Why?
|
| Endothelium, Vascular | 37 | 2019 | 4455 | 4.040 |
Why?
|
| Uterus | 16 | 2022 | 710 | 4.030 |
Why?
|
| Pre-Eclampsia | 19 | 2022 | 1196 | 3.860 |
Why?
|
| Matrix Metalloproteinase 9 | 11 | 2022 | 638 | 3.700 |
Why?
|
| Varicose Veins | 13 | 2020 | 154 | 3.610 |
Why?
|
| Placenta | 19 | 2023 | 1694 | 3.520 |
Why?
|
| Vascular Diseases | 11 | 2022 | 1155 | 3.210 |
Why?
|
| Nitric Oxide | 31 | 2021 | 2128 | 3.170 |
Why?
|
| Hypertension | 38 | 2023 | 8455 | 3.130 |
Why?
|
| Hypertension, Pregnancy-Induced | 9 | 2020 | 485 | 3.120 |
Why?
|
| Muscle Contraction | 26 | 2021 | 1241 | 2.850 |
Why?
|
| Vena Cava, Inferior | 11 | 2020 | 436 | 2.840 |
Why?
|
| Vasoconstrictor Agents | 30 | 2023 | 643 | 2.670 |
Why?
|
| Rats, Sprague-Dawley | 56 | 2022 | 8300 | 2.590 |
Why?
|
| Pregnancy, Animal | 11 | 2014 | 134 | 2.570 |
Why?
|
| Protein Kinase C | 24 | 2016 | 1227 | 2.520 |
Why?
|
| Calcium | 40 | 2016 | 5753 | 2.380 |
Why?
|
| Phenylephrine | 33 | 2016 | 301 | 2.140 |
Why?
|
| Cyclic GMP | 15 | 2017 | 408 | 2.110 |
Why?
|
| Pregnancy Complications, Cardiovascular | 11 | 2016 | 501 | 2.070 |
Why?
|
| Uterine Artery | 3 | 2020 | 36 | 2.060 |
Why?
|
| Estrogens | 13 | 2023 | 1562 | 2.030 |
Why?
|
| Uterine Contraction | 4 | 2022 | 93 | 1.960 |
Why?
|
| Receptor, Endothelin B | 5 | 2014 | 41 | 1.900 |
Why?
|
| Calcium Signaling | 11 | 2018 | 721 | 1.880 |
Why?
|
| Ischemia | 11 | 2022 | 1911 | 1.870 |
Why?
|
| Rats | 63 | 2022 | 24265 | 1.790 |
Why?
|
| Disintegrins | 3 | 2022 | 24 | 1.750 |
Why?
|
| ADAM Proteins | 4 | 2022 | 242 | 1.720 |
Why?
|
| Biological Factors | 3 | 2023 | 164 | 1.710 |
Why?
|
| Progesterone | 10 | 2022 | 773 | 1.670 |
Why?
|
| Blood Pressure | 31 | 2022 | 8541 | 1.670 |
Why?
|
| Hypertension, Pulmonary | 6 | 2022 | 1527 | 1.580 |
Why?
|
| Receptors, Estrogen | 11 | 2013 | 2186 | 1.530 |
Why?
|
| Estrogen Receptor beta | 5 | 2015 | 175 | 1.500 |
Why?
|
| Caveolin 1 | 4 | 2015 | 264 | 1.470 |
Why?
|
| Blood Vessels | 9 | 2017 | 1124 | 1.470 |
Why?
|
| Aorta | 21 | 2017 | 2057 | 1.450 |
Why?
|
| Estrogen Replacement Therapy | 6 | 2013 | 1202 | 1.430 |
Why?
|
| Gonadal Steroid Hormones | 8 | 2010 | 711 | 1.420 |
Why?
|
| Pregnancy | 55 | 2023 | 29087 | 1.380 |
Why?
|
| Neovascularization, Physiologic | 5 | 2021 | 1350 | 1.370 |
Why?
|
| Animals | 139 | 2023 | 168561 | 1.340 |
Why?
|
| Mesenteric Arteries | 5 | 2021 | 183 | 1.340 |
Why?
|
| Microvessels | 4 | 2022 | 544 | 1.220 |
Why?
|
| Angiotensin II | 10 | 2023 | 881 | 1.200 |
Why?
|
| Estrogen Receptor alpha | 5 | 2015 | 577 | 1.200 |
Why?
|
| Myometrium | 3 | 2022 | 181 | 1.180 |
Why?
|
| Potassium Chloride | 16 | 2013 | 238 | 1.170 |
Why?
|
| Pulmonary Artery | 6 | 2022 | 1911 | 1.170 |
Why?
|
| Glycosaminoglycans | 2 | 2020 | 624 | 1.120 |
Why?
|
| Placental Circulation | 4 | 2021 | 40 | 1.100 |
Why?
|
| Endothelin-1 | 7 | 2013 | 313 | 1.100 |
Why?
|
| Estradiol | 12 | 2013 | 2021 | 1.070 |
Why?
|
| Myocytes, Smooth Muscle | 6 | 2022 | 686 | 1.070 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 4 | 2018 | 552 | 1.070 |
Why?
|
| NG-Nitroarginine Methyl Ester | 16 | 2015 | 255 | 1.060 |
Why?
|
| Thrombospondins | 3 | 2022 | 197 | 1.040 |
Why?
|
| Adaptation, Physiological | 5 | 2016 | 1310 | 1.040 |
Why?
|
| Nitric Oxide Synthase | 10 | 2015 | 916 | 1.030 |
Why?
|
| Signal Transduction | 29 | 2020 | 23387 | 1.010 |
Why?
|
| Vasomotor System | 3 | 2016 | 209 | 1.000 |
Why?
|
| Angiotensin I | 1 | 2023 | 56 | 0.950 |
Why?
|
| Vasodilator Agents | 14 | 2013 | 976 | 0.950 |
Why?
|
| Venous Insufficiency | 2 | 2020 | 103 | 0.940 |
Why?
|
| Sodium Chloride, Dietary | 6 | 2011 | 281 | 0.940 |
Why?
|
| Biological Phenomena | 1 | 2023 | 28 | 0.920 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 2 | 2017 | 149 | 0.890 |
Why?
|
| Nitric Oxide Synthase Type III | 6 | 2013 | 689 | 0.860 |
Why?
|
| Enzyme Induction | 3 | 2013 | 475 | 0.850 |
Why?
|
| Menopause | 6 | 2012 | 1621 | 0.810 |
Why?
|
| Sodium, Dietary | 3 | 2015 | 418 | 0.790 |
Why?
|
| Aortic Aneurysm, Abdominal | 3 | 2020 | 1181 | 0.780 |
Why?
|
| Veins | 4 | 2015 | 769 | 0.770 |
Why?
|
| Placentation | 2 | 2020 | 82 | 0.760 |
Why?
|
| Endothelins | 8 | 2014 | 138 | 0.760 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2021 | 4414 | 0.760 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 2021 | 95 | 0.760 |
Why?
|
| Receptor, Endothelin A | 3 | 2014 | 58 | 0.710 |
Why?
|
| Receptors, Endothelin | 3 | 2011 | 58 | 0.670 |
Why?
|
| Receptors, Mineralocorticoid | 3 | 2015 | 164 | 0.660 |
Why?
|
| Enzyme Inhibitors | 20 | 2015 | 3800 | 0.640 |
Why?
|
| Acetylcholine | 11 | 2012 | 621 | 0.640 |
Why?
|
| Arteries | 5 | 2015 | 1118 | 0.630 |
Why?
|
| Sodium Chloride | 4 | 2006 | 625 | 0.620 |
Why?
|
| Potassium Channels, Tandem Pore Domain | 1 | 2018 | 58 | 0.620 |
Why?
|
| Epoprostenol | 4 | 2012 | 254 | 0.610 |
Why?
|
| Muscle Relaxation | 4 | 2012 | 142 | 0.600 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2017 | 58 | 0.600 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 3 | 2017 | 99 | 0.590 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2017 | 141 | 0.590 |
Why?
|
| Disease | 3 | 2017 | 681 | 0.590 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2021 | 1213 | 0.590 |
Why?
|
| Receptor, Angiotensin, Type 2 | 2 | 2023 | 67 | 0.570 |
Why?
|
| Isoenzymes | 9 | 2005 | 1725 | 0.570 |
Why?
|
| Coronary Vasospasm | 5 | 2004 | 88 | 0.550 |
Why?
|
| Calcium Channel Blockers | 7 | 2016 | 689 | 0.550 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2018 | 282 | 0.550 |
Why?
|
| Organ Specificity | 3 | 2017 | 2003 | 0.550 |
Why?
|
| Enzyme Assays | 1 | 2017 | 111 | 0.540 |
Why?
|
| Female | 82 | 2023 | 379592 | 0.540 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2021 | 495 | 0.540 |
Why?
|
| HELLP Syndrome | 1 | 2015 | 41 | 0.530 |
Why?
|
| Collagen | 3 | 2022 | 2684 | 0.530 |
Why?
|
| Vascular Resistance | 6 | 2013 | 936 | 0.530 |
Why?
|
| Isometric Contraction | 7 | 2013 | 147 | 0.510 |
Why?
|
| Drugs, Investigational | 1 | 2017 | 214 | 0.510 |
Why?
|
| Receptor, Angiotensin, Type 1 | 5 | 2023 | 152 | 0.510 |
Why?
|
| Testosterone | 9 | 2023 | 2401 | 0.500 |
Why?
|
| Calmodulin-Binding Proteins | 2 | 2015 | 249 | 0.500 |
Why?
|
| Phytoestrogens | 2 | 2012 | 61 | 0.490 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2019 | 10943 | 0.490 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2017 | 1801 | 0.480 |
Why?
|
| Intracellular Membranes | 3 | 2002 | 390 | 0.480 |
Why?
|
| Blood Circulation | 1 | 2015 | 251 | 0.480 |
Why?
|
| Collagen Type I | 1 | 2017 | 592 | 0.480 |
Why?
|
| Sex Characteristics | 6 | 2023 | 2585 | 0.480 |
Why?
|
| Disease Models, Animal | 12 | 2020 | 18006 | 0.470 |
Why?
|
| Litter Size | 3 | 2021 | 54 | 0.470 |
Why?
|
| Extracellular Matrix | 7 | 2020 | 1740 | 0.470 |
Why?
|
| Pancreatic Elastase | 2 | 2004 | 135 | 0.460 |
Why?
|
| Peptide Fragments | 3 | 2023 | 5095 | 0.460 |
Why?
|
| Renal Artery | 3 | 2015 | 398 | 0.460 |
Why?
|
| Placental Insufficiency | 2 | 2004 | 51 | 0.460 |
Why?
|
| Mesenteric Veins | 1 | 2013 | 89 | 0.450 |
Why?
|
| Protease Inhibitors | 3 | 2012 | 790 | 0.450 |
Why?
|
| Receptors, Epoprostenol | 1 | 2012 | 12 | 0.440 |
Why?
|
| Protein Kinase C-epsilon | 3 | 2007 | 43 | 0.430 |
Why?
|
| Coronary Vessels | 7 | 2004 | 3099 | 0.430 |
Why?
|
| Plant Preparations | 1 | 2013 | 94 | 0.430 |
Why?
|
| Cardiovascular Diseases | 8 | 2017 | 15108 | 0.420 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2021 | 3502 | 0.420 |
Why?
|
| Receptors, G-Protein-Coupled | 3 | 2015 | 1221 | 0.420 |
Why?
|
| Acidosis, Respiratory | 1 | 2012 | 37 | 0.420 |
Why?
|
| Up-Regulation | 5 | 2017 | 4211 | 0.420 |
Why?
|
| Gene Expression Regulation | 4 | 2020 | 12071 | 0.410 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channels | 1 | 2011 | 32 | 0.410 |
Why?
|
| Electrophysiological Phenomena | 1 | 2014 | 316 | 0.410 |
Why?
|
| Venous Pressure | 2 | 2008 | 56 | 0.410 |
Why?
|
| Escin | 1 | 2011 | 2 | 0.400 |
Why?
|
| RNA Interference | 1 | 2020 | 2890 | 0.390 |
Why?
|
| Blotting, Western | 8 | 2015 | 5180 | 0.390 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2011 | 115 | 0.390 |
Why?
|
| Pressoreceptors | 1 | 2010 | 100 | 0.380 |
Why?
|
| Airway Remodeling | 1 | 2012 | 132 | 0.380 |
Why?
|
| Down-Regulation | 5 | 2020 | 3001 | 0.370 |
Why?
|
| Dinoprost | 5 | 2003 | 138 | 0.370 |
Why?
|
| Substrate Specificity | 4 | 2017 | 1802 | 0.360 |
Why?
|
| Thorax | 1 | 2013 | 547 | 0.360 |
Why?
|
| Oxytocin | 3 | 2022 | 395 | 0.360 |
Why?
|
| Humans | 73 | 2023 | 742088 | 0.360 |
Why?
|
| Aorta, Thoracic | 8 | 2015 | 1080 | 0.360 |
Why?
|
| Male | 57 | 2023 | 349538 | 0.350 |
Why?
|
| Cardiovascular System | 2 | 2015 | 827 | 0.340 |
Why?
|
| Lower Extremity | 1 | 2017 | 1151 | 0.340 |
Why?
|
| Renal Circulation | 2 | 2009 | 333 | 0.330 |
Why?
|
| Muscles | 1 | 2014 | 1617 | 0.330 |
Why?
|
| Proteinuria | 2 | 2022 | 657 | 0.320 |
Why?
|
| Splanchnic Circulation | 1 | 2008 | 110 | 0.320 |
Why?
|
| Leukocyte Rolling | 1 | 2008 | 72 | 0.320 |
Why?
|
| Drug Design | 1 | 2014 | 1078 | 0.320 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2008 | 129 | 0.320 |
Why?
|
| Membrane Potentials | 6 | 2011 | 1135 | 0.310 |
Why?
|
| Developing Countries | 1 | 2020 | 2789 | 0.310 |
Why?
|
| Mesentery | 1 | 2008 | 205 | 0.310 |
Why?
|
| Potassium Channel Blockers | 3 | 2015 | 171 | 0.300 |
Why?
|
| Protein Kinase C-alpha | 1 | 2007 | 112 | 0.300 |
Why?
|
| Abdomen | 1 | 2013 | 1107 | 0.290 |
Why?
|
| Nitroprusside | 5 | 2012 | 275 | 0.290 |
Why?
|
| Enzyme Activation | 11 | 2007 | 3701 | 0.290 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2010 | 627 | 0.290 |
Why?
|
| Tissue Distribution | 5 | 2017 | 2335 | 0.280 |
Why?
|
| Calcium, Dietary | 1 | 2009 | 527 | 0.280 |
Why?
|
| Cardiovascular Agents | 1 | 2013 | 848 | 0.280 |
Why?
|
| Culture Techniques | 5 | 2004 | 554 | 0.270 |
Why?
|
| Gamma Rays | 1 | 2007 | 320 | 0.270 |
Why?
|
| Microcirculation | 2 | 2008 | 1285 | 0.270 |
Why?
|
| Organ Culture Techniques | 2 | 2019 | 808 | 0.270 |
Why?
|
| Eclampsia | 1 | 2006 | 58 | 0.270 |
Why?
|
| Nitrites | 4 | 2013 | 160 | 0.270 |
Why?
|
| Calmodulin | 1 | 2006 | 209 | 0.270 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2010 | 541 | 0.260 |
Why?
|
| Cytokines | 4 | 2022 | 7317 | 0.260 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2006 | 113 | 0.250 |
Why?
|
| Endothelial Cells | 5 | 2011 | 3455 | 0.250 |
Why?
|
| Rats, Inbred SHR | 5 | 2003 | 195 | 0.250 |
Why?
|
| Hyperglycemia | 1 | 2013 | 1368 | 0.250 |
Why?
|
| Estrus | 2 | 2014 | 82 | 0.250 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2010 | 1114 | 0.250 |
Why?
|
| Hemodynamics | 2 | 2017 | 4197 | 0.240 |
Why?
|
| Swine | 10 | 2004 | 5934 | 0.240 |
Why?
|
| Diltiazem | 3 | 2016 | 133 | 0.240 |
Why?
|
| Interleukin-6 | 2 | 2004 | 3199 | 0.240 |
Why?
|
| MicroRNAs | 1 | 2020 | 3731 | 0.240 |
Why?
|
| Kidney | 4 | 2009 | 7167 | 0.240 |
Why?
|
| Potassium Channels | 1 | 2007 | 562 | 0.230 |
Why?
|
| Cyclins | 1 | 2006 | 601 | 0.230 |
Why?
|
| Dilatation, Pathologic | 3 | 2013 | 520 | 0.230 |
Why?
|
| Anticoagulants | 1 | 2019 | 4595 | 0.230 |
Why?
|
| Placenta Diseases | 1 | 2006 | 195 | 0.230 |
Why?
|
| Fetal Growth Retardation | 2 | 2018 | 570 | 0.230 |
Why?
|
| Calcium Channels | 3 | 2009 | 621 | 0.230 |
Why?
|
| Aging | 3 | 2009 | 8626 | 0.230 |
Why?
|
| Cadherins | 1 | 2008 | 906 | 0.230 |
Why?
|
| Cerebrovascular Circulation | 1 | 2013 | 2732 | 0.220 |
Why?
|
| Osmolar Concentration | 5 | 2012 | 683 | 0.220 |
Why?
|
| Extracellular Space | 2 | 2002 | 594 | 0.220 |
Why?
|
| Metalloproteases | 1 | 2022 | 62 | 0.220 |
Why?
|
| Ferrets | 5 | 1995 | 194 | 0.210 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2013 | 1527 | 0.210 |
Why?
|
| Receptors, Oxytocin | 1 | 2022 | 66 | 0.210 |
Why?
|
| Nerve Tissue Proteins | 1 | 2015 | 4465 | 0.210 |
Why?
|
| Tissue Culture Techniques | 2 | 2017 | 291 | 0.210 |
Why?
|
| Guanylate Cyclase | 2 | 2013 | 201 | 0.200 |
Why?
|
| Aldosterone | 3 | 2011 | 876 | 0.200 |
Why?
|
| Fura-2 | 5 | 2001 | 109 | 0.200 |
Why?
|
| RNA, Messenger | 5 | 2022 | 13029 | 0.200 |
Why?
|
| Monocrotaline | 2 | 2012 | 26 | 0.200 |
Why?
|
| Cells, Cultured | 7 | 2021 | 19223 | 0.200 |
Why?
|
| Adrenergic alpha-Agonists | 4 | 2004 | 177 | 0.200 |
Why?
|
| Oligopeptides | 3 | 2014 | 1176 | 0.190 |
Why?
|
| Nitrates | 3 | 2013 | 265 | 0.190 |
Why?
|
| Eicosanoids | 2 | 2002 | 278 | 0.190 |
Why?
|
| Connexins | 1 | 2022 | 359 | 0.190 |
Why?
|
| Receptors, Adrenergic, alpha | 3 | 2010 | 149 | 0.190 |
Why?
|
| Antihypertensive Agents | 2 | 2012 | 2043 | 0.190 |
Why?
|
| Maleimides | 2 | 2016 | 112 | 0.190 |
Why?
|
| Reactive Oxygen Species | 3 | 2016 | 2077 | 0.190 |
Why?
|
| Scleroderma, Localized | 2 | 2013 | 79 | 0.180 |
Why?
|
| Apoptosis | 3 | 2021 | 9715 | 0.180 |
Why?
|
| Muscle Tonus | 3 | 2012 | 81 | 0.180 |
Why?
|
| Semen | 1 | 2022 | 316 | 0.180 |
Why?
|
| Thrombophlebitis | 2 | 2013 | 309 | 0.180 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2002 | 287 | 0.180 |
Why?
|
| Mice, Knockout | 5 | 2015 | 14554 | 0.180 |
Why?
|
| Leukocytes | 1 | 2008 | 2039 | 0.180 |
Why?
|
| Regional Blood Flow | 2 | 2019 | 1525 | 0.180 |
Why?
|
| Sodium | 2 | 2002 | 1627 | 0.180 |
Why?
|
| Oxytocics | 1 | 2000 | 68 | 0.170 |
Why?
|
| Catheter Ablation | 1 | 2013 | 2746 | 0.170 |
Why?
|
| Spironolactone | 2 | 2015 | 382 | 0.170 |
Why?
|
| Models, Animal | 4 | 2010 | 2170 | 0.170 |
Why?
|
| Oxidative Stress | 3 | 2009 | 3081 | 0.170 |
Why?
|
| Phosphorylation | 5 | 2016 | 8436 | 0.170 |
Why?
|
| Aorta, Abdominal | 2 | 2017 | 645 | 0.170 |
Why?
|
| Collagen Type IV | 1 | 2019 | 139 | 0.170 |
Why?
|
| Hindlimb | 1 | 2021 | 505 | 0.170 |
Why?
|
| Phenols | 2 | 2015 | 501 | 0.170 |
Why?
|
| Oxadiazoles | 3 | 2004 | 93 | 0.160 |
Why?
|
| Trophoblasts | 1 | 2019 | 215 | 0.160 |
Why?
|
| Membrane Proteins | 1 | 2015 | 7873 | 0.160 |
Why?
|
| Animals, Newborn | 2 | 2019 | 2723 | 0.160 |
Why?
|
| Risk Factors | 10 | 2020 | 72145 | 0.160 |
Why?
|
| Immunoblotting | 4 | 2008 | 1683 | 0.150 |
Why?
|
| Receptors, Progesterone | 1 | 2022 | 1097 | 0.150 |
Why?
|
| Cell Cycle | 1 | 2006 | 2964 | 0.150 |
Why?
|
| Lipoproteins, LDL | 1 | 2001 | 628 | 0.150 |
Why?
|
| Kidney Diseases | 1 | 2009 | 2145 | 0.150 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2011 | 371 | 0.150 |
Why?
|
| Fertility | 1 | 2022 | 770 | 0.150 |
Why?
|
| Enzyme Activators | 1 | 2017 | 57 | 0.150 |
Why?
|
| Gelatinases | 1 | 2017 | 94 | 0.150 |
Why?
|
| Cysteine | 1 | 2022 | 873 | 0.150 |
Why?
|
| Enzyme Precursors | 1 | 2017 | 176 | 0.150 |
Why?
|
| Ion Transport | 3 | 2003 | 320 | 0.140 |
Why?
|
| Rats, Inbred WKY | 4 | 2001 | 158 | 0.140 |
Why?
|
| Gestational Age | 2 | 2017 | 3490 | 0.140 |
Why?
|
| rho-Associated Kinases | 2 | 2009 | 279 | 0.140 |
Why?
|
| Hyperhomocysteinemia | 1 | 2017 | 124 | 0.140 |
Why?
|
| Phorbol 12,13-Dibutyrate | 3 | 2001 | 40 | 0.140 |
Why?
|
| Quinoxalines | 3 | 2004 | 288 | 0.140 |
Why?
|
| Peripheral Arterial Disease | 2 | 2017 | 1184 | 0.140 |
Why?
|
| Amino Acid Motifs | 1 | 2019 | 936 | 0.140 |
Why?
|
| Endopeptidases | 1 | 2020 | 772 | 0.140 |
Why?
|
| Mice | 8 | 2020 | 81045 | 0.140 |
Why?
|
| Myosin Light Chains | 1 | 2016 | 121 | 0.140 |
Why?
|
| Sex Factors | 6 | 2010 | 10392 | 0.140 |
Why?
|
| Tetraethylammonium | 1 | 2015 | 58 | 0.140 |
Why?
|
| Lung | 2 | 2012 | 9826 | 0.140 |
Why?
|
| Dimerization | 1 | 2017 | 893 | 0.130 |
Why?
|
| Birth Weight | 2 | 2019 | 2068 | 0.130 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2017 | 279 | 0.130 |
Why?
|
| Verapamil | 3 | 2004 | 244 | 0.130 |
Why?
|
| Nitriles | 2 | 2010 | 952 | 0.130 |
Why?
|
| Renin-Angiotensin System | 2 | 2015 | 759 | 0.130 |
Why?
|
| Maternal Health Services | 1 | 2020 | 452 | 0.130 |
Why?
|
| Cell Hypoxia | 1 | 2017 | 675 | 0.130 |
Why?
|
| Protein Transport | 3 | 2007 | 1988 | 0.130 |
Why?
|
| Viper Venoms | 1 | 2014 | 14 | 0.130 |
Why?
|
| Angiogenic Proteins | 1 | 2015 | 104 | 0.130 |
Why?
|
| Tetradecanoylphorbol Acetate | 4 | 2004 | 821 | 0.120 |
Why?
|
| Immunohistochemistry | 5 | 2015 | 11363 | 0.120 |
Why?
|
| Labor, Obstetric | 1 | 2017 | 333 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 4751 | 0.120 |
Why?
|
| Heart Injuries | 1 | 2015 | 209 | 0.110 |
Why?
|
| Carotid Arteries | 2 | 2015 | 952 | 0.110 |
Why?
|
| Mitogens | 1 | 1993 | 232 | 0.110 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 1780 | 0.110 |
Why?
|
| Hydrostatic Pressure | 1 | 2013 | 106 | 0.110 |
Why?
|
| Coronary Circulation | 1 | 1999 | 1572 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 3 | 2009 | 489 | 0.110 |
Why?
|
| Thromboxane-A Synthase | 1 | 2012 | 34 | 0.110 |
Why?
|
| Caffeine | 3 | 2003 | 699 | 0.110 |
Why?
|
| Pyrazoles | 2 | 2015 | 1970 | 0.110 |
Why?
|
| Plants, Medicinal | 1 | 2013 | 167 | 0.110 |
Why?
|
| Leg | 1 | 2017 | 1110 | 0.110 |
Why?
|
| Reference Values | 3 | 2008 | 4982 | 0.110 |
Why?
|
| Prostaglandins I | 1 | 2011 | 13 | 0.110 |
Why?
|
| Ammonium Chloride | 1 | 2012 | 74 | 0.110 |
Why?
|
| Protein Isoforms | 2 | 2011 | 1727 | 0.100 |
Why?
|
| Indoles | 2 | 2016 | 1834 | 0.100 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2012 | 109 | 0.100 |
Why?
|
| Age Factors | 3 | 2020 | 18355 | 0.100 |
Why?
|
| Potassium | 3 | 1993 | 1336 | 0.100 |
Why?
|
| Cholinergic Agonists | 1 | 2012 | 74 | 0.100 |
Why?
|
| Protein Multimerization | 1 | 2017 | 971 | 0.100 |
Why?
|
| Peptides, Cyclic | 1 | 2014 | 401 | 0.100 |
Why?
|
| Nucleic Acid Conformation | 1 | 2015 | 914 | 0.100 |
Why?
|
| Diosmin | 1 | 2011 | 6 | 0.100 |
Why?
|
| Fetal Development | 1 | 2017 | 767 | 0.100 |
Why?
|
| Adrenergic alpha-1 Receptor Agonists | 1 | 2011 | 19 | 0.100 |
Why?
|
| Tyrosine | 2 | 1996 | 1460 | 0.100 |
Why?
|
| Norepinephrine | 3 | 1990 | 909 | 0.100 |
Why?
|
| Muscle, Smooth | 2 | 1992 | 933 | 0.100 |
Why?
|
| Echinomycin | 1 | 2010 | 2 | 0.100 |
Why?
|
| Saphenous Vein | 3 | 2011 | 531 | 0.100 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2012 | 329 | 0.100 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 1 | 2011 | 48 | 0.100 |
Why?
|
| Myography | 1 | 2012 | 109 | 0.100 |
Why?
|
| Naphthalenes | 2 | 2004 | 194 | 0.100 |
Why?
|
| Chronic Disease | 2 | 2017 | 9144 | 0.100 |
Why?
|
| Sapogenins | 1 | 2010 | 3 | 0.100 |
Why?
|
| Dermatitis | 1 | 2013 | 197 | 0.100 |
Why?
|
| Ginsenosides | 1 | 2010 | 11 | 0.100 |
Why?
|
| Butadienes | 1 | 2010 | 110 | 0.100 |
Why?
|
| Probability | 2 | 2008 | 2502 | 0.100 |
Why?
|
| Phytotherapy | 1 | 2013 | 298 | 0.100 |
Why?
|
| Integrins | 1 | 2015 | 845 | 0.090 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2021 | 1625 | 0.090 |
Why?
|
| Physical Stimulation | 1 | 2012 | 525 | 0.090 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2013 | 608 | 0.090 |
Why?
|
| Benzoquinones | 1 | 2010 | 201 | 0.090 |
Why?
|
| Subcellular Fractions | 2 | 2001 | 547 | 0.090 |
Why?
|
| Hypertrophy | 1 | 2012 | 568 | 0.090 |
Why?
|
| Receptors, Angiotensin | 1 | 2010 | 142 | 0.090 |
Why?
|
| Progestins | 1 | 2012 | 303 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2012 | 9941 | 0.090 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2012 | 419 | 0.090 |
Why?
|
| Hematologic Diseases | 1 | 2014 | 498 | 0.090 |
Why?
|
| Estrogen Antagonists | 1 | 2010 | 151 | 0.090 |
Why?
|
| Gene Expression | 2 | 2021 | 7790 | 0.090 |
Why?
|
| Catalytic Domain | 1 | 2012 | 699 | 0.090 |
Why?
|
| Renin | 1 | 2011 | 642 | 0.090 |
Why?
|
| Inflammation | 1 | 2009 | 10578 | 0.090 |
Why?
|
| Molecular Sequence Data | 3 | 2012 | 18112 | 0.080 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 1996 | 2455 | 0.080 |
Why?
|
| Lactams, Macrocyclic | 1 | 2010 | 319 | 0.080 |
Why?
|
| Cell Separation | 3 | 2001 | 1749 | 0.080 |
Why?
|
| Histone Demethylases | 1 | 2011 | 320 | 0.080 |
Why?
|
| Genomic Imprinting | 1 | 2010 | 331 | 0.080 |
Why?
|
| Cytosol | 2 | 2007 | 901 | 0.080 |
Why?
|
| Biopsy | 1 | 2020 | 6756 | 0.080 |
Why?
|
| Orchiectomy | 2 | 2001 | 466 | 0.080 |
Why?
|
| Ovariectomy | 2 | 2001 | 660 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2009 | 480 | 0.080 |
Why?
|
| Carbon Dioxide | 1 | 2012 | 1141 | 0.080 |
Why?
|
| Cromakalim | 1 | 2007 | 19 | 0.080 |
Why?
|
| Phenotype | 2 | 2017 | 16331 | 0.070 |
Why?
|
| Potassium Channels, Calcium-Activated | 1 | 2007 | 49 | 0.070 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2007 | 19 | 0.070 |
Why?
|
| Rabbits | 5 | 2011 | 4886 | 0.070 |
Why?
|
| Ankle Brachial Index | 2 | 2017 | 154 | 0.070 |
Why?
|
| Losartan | 1 | 2009 | 298 | 0.070 |
Why?
|
| Ethinyl Estradiol | 1 | 2007 | 116 | 0.070 |
Why?
|
| Time Factors | 6 | 2010 | 40054 | 0.070 |
Why?
|
| Organ Size | 1 | 2012 | 2253 | 0.070 |
Why?
|
| Sympathetic Fibers, Postganglionic | 1 | 2006 | 13 | 0.070 |
Why?
|
| Metformin | 1 | 2013 | 829 | 0.070 |
Why?
|
| NAD | 1 | 2010 | 594 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2015 | 2502 | 0.070 |
Why?
|
| Indomethacin | 1 | 2007 | 331 | 0.070 |
Why?
|
| Synovial Membrane | 1 | 2009 | 506 | 0.070 |
Why?
|
| Prosthesis Design | 1 | 2013 | 2110 | 0.070 |
Why?
|
| Protein Kinases | 1 | 1993 | 1638 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2022 | 10472 | 0.070 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 1 | 2009 | 378 | 0.070 |
Why?
|
| Cytoskeleton | 2 | 2007 | 1185 | 0.070 |
Why?
|
| Lymphokines | 1 | 2009 | 949 | 0.070 |
Why?
|
| Feedback, Physiological | 1 | 2008 | 479 | 0.070 |
Why?
|
| Piperidines | 1 | 2014 | 1602 | 0.070 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2007 | 275 | 0.070 |
Why?
|
| Aneurysm | 1 | 2009 | 339 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 3 | 1995 | 2505 | 0.070 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2009 | 453 | 0.070 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2007 | 876 | 0.070 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2013 | 1989 | 0.070 |
Why?
|
| Guinea Pigs | 1 | 2007 | 1386 | 0.070 |
Why?
|
| Portal Vein | 3 | 1992 | 437 | 0.070 |
Why?
|
| Recombinant Proteins | 1 | 1995 | 6608 | 0.060 |
Why?
|
| Models, Molecular | 1 | 2015 | 5454 | 0.060 |
Why?
|
| Ligands | 1 | 2012 | 3293 | 0.060 |
Why?
|
| Water-Electrolyte Balance | 1 | 2006 | 346 | 0.060 |
Why?
|
| Vasculitis | 1 | 2009 | 521 | 0.060 |
Why?
|
| Equipment Design | 1 | 2013 | 3582 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2015 | 4328 | 0.060 |
Why?
|
| Capillary Permeability | 1 | 2008 | 798 | 0.060 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 15056 | 0.060 |
Why?
|
| Coronary Restenosis | 1 | 2007 | 424 | 0.060 |
Why?
|
| Heart Valve Prosthesis | 1 | 2013 | 1486 | 0.060 |
Why?
|
| Immune System | 1 | 2009 | 804 | 0.060 |
Why?
|
| Intracellular Fluid | 1 | 2003 | 203 | 0.060 |
Why?
|
| Atherosclerosis | 2 | 2012 | 3428 | 0.060 |
Why?
|
| Constriction | 1 | 2003 | 181 | 0.060 |
Why?
|
| Random Allocation | 1 | 2008 | 2425 | 0.060 |
Why?
|
| Lung Diseases | 1 | 2014 | 1884 | 0.060 |
Why?
|
| Blood Coagulation | 1 | 2009 | 1126 | 0.060 |
Why?
|
| Pregnancy Complications | 1 | 2017 | 2861 | 0.060 |
Why?
|
| 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 1 | 2002 | 36 | 0.060 |
Why?
|
| Calcium Channel Agonists | 1 | 2002 | 29 | 0.060 |
Why?
|
| Coronary Artery Disease | 1 | 2003 | 6454 | 0.060 |
Why?
|
| Calcium Radioisotopes | 1 | 2002 | 9 | 0.060 |
Why?
|
| Structure-Activity Relationship | 1 | 2009 | 3133 | 0.060 |
Why?
|
| Stress, Mechanical | 2 | 2016 | 1684 | 0.050 |
Why?
|
| Phorbol Esters | 2 | 2001 | 111 | 0.050 |
Why?
|
| Imidazoles | 1 | 2009 | 1205 | 0.050 |
Why?
|
| Kidney Medulla | 1 | 2002 | 182 | 0.050 |
Why?
|
| Sodium-Calcium Exchanger | 1 | 2002 | 91 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 2276 | 0.050 |
Why?
|
| Lipid Peroxides | 1 | 2001 | 73 | 0.050 |
Why?
|
| Stimulation, Chemical | 2 | 1999 | 326 | 0.050 |
Why?
|
| Wound Healing | 1 | 2013 | 2781 | 0.050 |
Why?
|
| Natriuresis | 1 | 2001 | 124 | 0.050 |
Why?
|
| China | 2 | 2017 | 2246 | 0.050 |
Why?
|
| Hypoglycemic Agents | 1 | 2013 | 2866 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2008 | 14720 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2021 | 62966 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 5522 | 0.050 |
Why?
|
| Isotonic Solutions | 1 | 2001 | 119 | 0.050 |
Why?
|
| Cell Movement | 1 | 2013 | 5212 | 0.050 |
Why?
|
| Base Sequence | 1 | 2012 | 12797 | 0.050 |
Why?
|
| Amino Acid Sequence | 2 | 2006 | 13814 | 0.050 |
Why?
|
| Culture Media | 1 | 2002 | 902 | 0.050 |
Why?
|
| Hypertension, Renal | 1 | 2001 | 177 | 0.050 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 2 | 1991 | 57 | 0.050 |
Why?
|
| Models, Biological | 1 | 2017 | 9581 | 0.050 |
Why?
|
| Castration | 1 | 2000 | 158 | 0.050 |
Why?
|
| Erythrocytes | 1 | 2009 | 2452 | 0.040 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2001 | 215 | 0.040 |
Why?
|
| Methylene Blue | 1 | 2000 | 155 | 0.040 |
Why?
|
| Monocytes | 1 | 2009 | 2593 | 0.040 |
Why?
|
| Heart Ventricles | 1 | 2012 | 3801 | 0.040 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 1 | 1998 | 68 | 0.040 |
Why?
|
| Carbazoles | 1 | 2001 | 226 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 1640 | 0.040 |
Why?
|
| Pyrrolidines | 1 | 2001 | 342 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2004 | 2271 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2004 | 2885 | 0.040 |
Why?
|
| Biological Transport | 2 | 1994 | 2119 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2009 | 2506 | 0.040 |
Why?
|
| Staurosporine | 1 | 1999 | 251 | 0.040 |
Why?
|
| Isoquinolines | 2 | 1991 | 368 | 0.040 |
Why?
|
| Postmenopause | 1 | 2007 | 2461 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2004 | 1608 | 0.040 |
Why?
|
| Lipoproteins | 1 | 2003 | 876 | 0.040 |
Why?
|
| Carcinogens | 1 | 2000 | 466 | 0.040 |
Why?
|
| Perfusion | 1 | 2002 | 1359 | 0.040 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2001 | 555 | 0.040 |
Why?
|
| Diet | 2 | 2008 | 7923 | 0.040 |
Why?
|
| Obesity | 1 | 1999 | 12705 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2017 | 21719 | 0.040 |
Why?
|
| Arginine | 1 | 2001 | 944 | 0.040 |
Why?
|
| Pyridines | 1 | 2009 | 2818 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2007 | 2906 | 0.040 |
Why?
|
| Body Weight | 1 | 2008 | 4664 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2002 | 1284 | 0.040 |
Why?
|
| Genotype | 1 | 2011 | 12946 | 0.040 |
Why?
|
| Myocardium | 1 | 2009 | 4775 | 0.040 |
Why?
|
| Receptors, Androgen | 1 | 2003 | 1057 | 0.040 |
Why?
|
| Serotonin | 1 | 2001 | 1024 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2004 | 3913 | 0.030 |
Why?
|
| Vitamin D | 1 | 2009 | 3211 | 0.030 |
Why?
|
| Peptides | 1 | 2007 | 4392 | 0.030 |
Why?
|
| Differential Threshold | 1 | 1994 | 80 | 0.030 |
Why?
|
| Phosphotyrosine | 1 | 1995 | 457 | 0.030 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1996 | 494 | 0.030 |
Why?
|
| Mitochondria | 1 | 2007 | 3520 | 0.030 |
Why?
|
| Homocysteine | 1 | 2017 | 647 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 1996 | 8925 | 0.030 |
Why?
|
| Hypertonic Solutions | 1 | 1993 | 93 | 0.030 |
Why?
|
| Mammals | 1 | 1998 | 1135 | 0.030 |
Why?
|
| Fluorescent Dyes | 1 | 2001 | 1915 | 0.030 |
Why?
|
| Logistic Models | 2 | 2017 | 13403 | 0.030 |
Why?
|
| Middle Aged | 4 | 2017 | 213127 | 0.030 |
Why?
|
| Sarcolemma | 1 | 1991 | 66 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2012 | 25575 | 0.030 |
Why?
|
| 11-beta-Hydroxysteroid Dehydrogenase Type 2 | 1 | 2011 | 16 | 0.030 |
Why?
|
| Cell Compartmentation | 1 | 1991 | 402 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 3510 | 0.020 |
Why?
|
| Prevalence | 2 | 2017 | 15194 | 0.020 |
Why?
|
| Microscopy | 1 | 1995 | 903 | 0.020 |
Why?
|
| Piperazines | 2 | 1991 | 2488 | 0.020 |
Why?
|
| Adult | 1 | 2023 | 213712 | 0.020 |
Why?
|
| Sarcoplasmic Reticulum | 1 | 1987 | 158 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 17400 | 0.020 |
Why?
|
| Aged | 3 | 2017 | 162944 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2017 | 9846 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 12242 | 0.010 |
Why?
|
| Rats, Inbred Dahl | 1 | 2002 | 35 | 0.010 |
Why?
|
| Ion Channels | 1 | 1987 | 1056 | 0.010 |
Why?
|
| Guanidines | 1 | 2002 | 191 | 0.010 |
Why?
|
| HEK293 Cells | 1 | 2011 | 4200 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2002 | 534 | 0.010 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 2 | 1990 | 87 | 0.010 |
Why?
|
| Thionucleotides | 2 | 1990 | 107 | 0.010 |
Why?
|
| Guanosine Triphosphate | 2 | 1990 | 321 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2002 | 13655 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 1987 | 2867 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2017 | 23320 | 0.010 |
Why?
|
| Glomerular Filtration Rate | 1 | 2002 | 2167 | 0.010 |
Why?
|
| Myosin-Light-Chain Kinase | 1 | 1992 | 100 | 0.010 |
Why?
|
| Heart Rate | 1 | 2002 | 4091 | 0.010 |
Why?
|
| Egtazic Acid | 1 | 1990 | 173 | 0.010 |
Why?
|
| Type C Phospholipases | 1 | 1990 | 292 | 0.010 |
Why?
|
| Buffers | 1 | 1989 | 147 | 0.010 |
Why?
|
| Methods | 1 | 1989 | 1128 | 0.010 |
Why?
|
| Cell Division | 1 | 1996 | 4564 | 0.000 |
Why?
|
| Permeability | 1 | 1989 | 738 | 0.000 |
Why?
|
| GTP-Binding Proteins | 1 | 1989 | 970 | 0.000 |
Why?
|